IVF Booster Offered in Canada But Not US
By Alison Motluk,
Canadian Medical Association Journal
| 01. 14. 2015
[Quotes CGS's Marcy Darnovsky]
Untitled Document
A new fertility treatment that purports to help older women get pregnant by boosting the energy in their eggs is now being offered in Toronto, but nowhere else in North America. A trial in the US was voluntarily suspended after the Food and Drug Administration suggested the treatment may be considered an "investigational new drug" requiring approval. In Canada, it may fall outside regulation, though Health Canada has not made any formal response to date.
The treatment, called Augment, involves extracting mitochondria, a cell's energy supply, from a woman's own ovarian stem cells and injecting them into her eggs during in vitro fertilization. In December 2014, OvaScience, the US-based company that developed Augment, announced that the treatment would be offered commercially. No clinical data on efficacy were provided, though they noted that 150 women had been enrolled in experimental trials at four sites worldwide. These include the Toronto Centre for Advanced Reproductive Technology (TCART) and clinics in London, Istanbul and Dubai. Company Chief Executive Officer Michelle Dipp said they expected Augment would be used in approximately 1000 paying patients in 2015....
Related Articles
By Katie Hunt, CNN | 07.30.2025
Scientists are exploring ways to mimic the origins of human life without two fundamental components: sperm and egg.
They are coaxing clusters of stem cells – programmable cells that can transform into many different specialized cell types – to form...
By Rob Stein, NPR [cites CGS' Katie Hasson] | 08.06.2025
A Chinese scientist horrified the world in 2018 when he revealed he had secretly engineered the birth of the world's first gene-edited babies.
His work was reviled as reckless and unethical because, among other reasons, gene-editing was so new...
By Arthur Caplan and James Tabery, Scientific American | 07.28.2025
An understandable ethics outcry greeted the June announcement of a software platform that offers aspiring parents “genetic optimization” of their embryos. Touted by Nucleus Genomics’ CEO Kian Sadeghi, the $5,999 service, dubbed “Nucleus Embryo,” promised optimization of...
By Hannah Devlin, The Guardian | 07.05.2025
Scientists are just a few years from creating viable human sex cells in the lab, according to an internationally renowned pioneer of the field, who says the advance could open up biology-defying possibilities for reproduction.
Speaking to the Guardian, Prof...